A MULTI-COUNTRY RETROSPECTIVE CHART REVIEW OF TREATMENT PATTERNS AND RESOURCE USE IN PATIENTS WITH NEWLY DIAGNOSED PH-NEGATIVE B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA UNDERGOING FIRST-LINE CONSOLIDATION THERAPY
Author(s)
Hongbo Yang, PhD1, Mandy Du, PhD1, Xinglei Chai, PhD1, Jingyi Liu, MBI2, Zoey Kang, MS1, Faraz Zaman, MD3, Selina Luger, MD4, Anna Gautam, MS5, Diana Boyko, MA3;
1Analysis Group, Boston, MA, USA, 2Analysis Group, Toronto, ON, Canada, 3Amgen, Thousand Oaks, CA, USA, 4University of Pennsylvania, Philadelphia, PA, USA, 5Amgen, London, United Kingdom
1Analysis Group, Boston, MA, USA, 2Analysis Group, Toronto, ON, Canada, 3Amgen, Thousand Oaks, CA, USA, 4University of Pennsylvania, Philadelphia, PA, USA, 5Amgen, London, United Kingdom
OBJECTIVES: Assess treatment patterns and healthcare resource utilization (HRU) among patients with newly diagnosed Ph-negative (ND Ph−) B-cell acute lymphoblastic leukemia (ALL) from the initiation of 1L consolidation with chemotherapy and/or hematopoietic stem-cell transplant (HSCT).
METHODS: This retrospective chart review was conducted in 8 countries across North America and Europe. Patients who were in a measurable residual disease negative complete remission following induction +/- intensification chemotherapy and initiated 1L consolidation chemotherapy and/or HSCT (index date) between January 2018 and June 2023 were included. Treatments and HRU were assessed from index until loss of follow-up or death. Results were stratified by region (North America and Europe) and consolidation therapy received (chemotherapy only, chemotherapy + HSCT, or HSCT only).
RESULTS: 928 eligible patients (mean age 47.6 years; 62.6% male) were included. Hyper-CVAD was the most common consolidation regimen in patients who received chemotherapy only (31.5% and 24.8% in North America and Europe, respectively). Other common regimens included ALL PETHEMA (18.9% and 12.4%, respectively), GMALL (10.8% and 12.9%, respectively), and CALGB (17.1% and 12.4%, respectively). For chemotherapy + HSCT patients, hyper-CVAD (38.7% and 20.6%, respectively) and GMALL (22.6% and 29.1%, respectively) were most common. In North America, 44% of chemotherapy only patients required hospitalization (mean 2.0 hospitalizations per patient, 18.9 days mean length of stay [LOS]). All patients receiving HSCT required hospitalization (chemotherapy + HSCT: mean 1.4 hospitalizations, 25.9 days LOS; HSCT only: mean 1.1 hospitalizations, 30.3 days LOS). In Europe, 46% of chemotherapy only patients required hospitalization, with patients experiencing 3.1, 2.0, and 1.3 hospitalizations for chemotherapy only, chemotherapy + HSCT, and HSCT only, respectively. The mean LOS per hospitalization was 32.6, 39.3, and 36.3 days, respectively.
CONCLUSIONS: Hospitalizations appeared longer and more frequent in Europe than North America. Regardless of regimen, observed HRU underscores the need for innovative frontline ALL therapies to reduce HRU burden.
METHODS: This retrospective chart review was conducted in 8 countries across North America and Europe. Patients who were in a measurable residual disease negative complete remission following induction +/- intensification chemotherapy and initiated 1L consolidation chemotherapy and/or HSCT (index date) between January 2018 and June 2023 were included. Treatments and HRU were assessed from index until loss of follow-up or death. Results were stratified by region (North America and Europe) and consolidation therapy received (chemotherapy only, chemotherapy + HSCT, or HSCT only).
RESULTS: 928 eligible patients (mean age 47.6 years; 62.6% male) were included. Hyper-CVAD was the most common consolidation regimen in patients who received chemotherapy only (31.5% and 24.8% in North America and Europe, respectively). Other common regimens included ALL PETHEMA (18.9% and 12.4%, respectively), GMALL (10.8% and 12.9%, respectively), and CALGB (17.1% and 12.4%, respectively). For chemotherapy + HSCT patients, hyper-CVAD (38.7% and 20.6%, respectively) and GMALL (22.6% and 29.1%, respectively) were most common. In North America, 44% of chemotherapy only patients required hospitalization (mean 2.0 hospitalizations per patient, 18.9 days mean length of stay [LOS]). All patients receiving HSCT required hospitalization (chemotherapy + HSCT: mean 1.4 hospitalizations, 25.9 days LOS; HSCT only: mean 1.1 hospitalizations, 30.3 days LOS). In Europe, 46% of chemotherapy only patients required hospitalization, with patients experiencing 3.1, 2.0, and 1.3 hospitalizations for chemotherapy only, chemotherapy + HSCT, and HSCT only, respectively. The mean LOS per hospitalization was 32.6, 39.3, and 36.3 days, respectively.
CONCLUSIONS: Hospitalizations appeared longer and more frequent in Europe than North America. Regardless of regimen, observed HRU underscores the need for innovative frontline ALL therapies to reduce HRU burden.
Conference/Value in Health Info
2026-05, ISPOR 2026, Philadelphia, PA, USA
Value in Health, Volume 29, Issue S6
Code
SA15
Topic
Study Approaches
Disease
No Additional Disease & Conditions/Specialized Treatment Areas, SDC: Oncology